# HS-20089

Source: https://onco.cc/drugs/hs-20089/  
OnCo record `hs-20089` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

HS-20089 is an experimental antibody-drug conjugate from Hansoh BioMedical R&D in phase 3 trials for ovarian cancer and endometrial cancer, with its target not yet stated publicly.

## Summary

HS-20089 is an antibody-drug conjugate developed by Hansoh BioMedical R&D. The sponsor describes its target as B7-H4, which OnCo does not yet have a target page for. The sponsor states: HS-20089 is a humanised IgG1 anti-B7-H4 monoclonal antibody conjugated to a topoisomerase I inhibitor payload via a protease-cleavable linker (average drug-to-antibody ratio of about 6), delivering the payload to B7-H4-expressing tumour cells, given intravenously every three weeks in ovarian and endometrial cancer. ClinicalTrials.gov describes the intervention as: All patients will receive intravenous HS-20089 once every three weeks (Q3W) until experiencing objective disease progression (except for study drug treatment beyond progression) or meeting other protocol-specified criteria of study treatmen. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06855069 (HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer), in ovarian cancer and endometrial cancer. The largest, NCT06855069, plans to enrol 468 participants with primary completion expected 2027-03-07. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: ADC
- Mechanism: HS-20089 is a humanised IgG1 anti-B7-H4 monoclonal antibody conjugated to a topoisomerase I inhibitor payload via a protease-cleavable linker (average drug-to-antibody ratio of about 6), delivering the payload to B7-H4-expressing tumour cells, given intravenously every three weeks in ovarian and endometrial cancer.

## Sources

- ClinicalTrials.gov: trials of HS-20089: https://clinicaltrials.gov/search?intr=HS-20089

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- targets: [B7-H4 (VTCN1)](https://onco.cc/targets/b7h4/)
- companies: [Hansoh Pharmaceutical](https://onco.cc/companies/hansoh-pharma/)
- trials: [HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer](https://onco.cc/trials/nct06855069/), [HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer](https://onco.cc/trials/nct06014190/)

---
JSON: https://onco.cc/api/v1/entities/hs-20089.json